Altimmune Data From AI-Based Analysis Of Biopsies From IMPACT Phase 2b Trial Of Pemvidutide Demonstrates Reductions In Proportionate Areas Of Early, Advanced And Total Liver FibrosisAt 24 Weeks
Benzinga Newsdesk 1 year ago
News
Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced results from an artificial
Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced results from an artificial intelligence (AI)-based analysis of biopsies from the IMPACT Phase 2b trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH).
The AI-based pathology tool Liver Explore™ showed that pemvidutide treatment resulted in significant reductions in the proportionate areas of early, advanced and total liver fibrosis compared to placebo at 24 weeks. These data are supported by significant improvements in non-invasive markers of fibrosis compared to placebo. The AI-based analysis will be presented on Saturday, November 8, in a late-breaking poster session at The Liver Meeting 2025, hosted by the American Association for the Study of Liver Diseases (AASLD) in Washington, D.C.